-
公开(公告)号:USD1049371S1
公开(公告)日:2024-10-29
申请号:US29831175
申请日:2022-03-17
设计人: John Kenneth Hainsworth , Matthew John Garwood , Matthew Ian Murchie , Hong Choo Tang , Jason Robinson
摘要: FIG. 1 is a top, front, left side perspective view of an infusion pump cassette;
FIG. 2 is a front elevation view thereof;
FIG. 3 is a rear elevation view thereof;
FIG. 4 is a left side elevation view thereof;
FIG. 5 is a right side elevation view thereof;
FIG. 6 is a top plan view thereof;
FIG. 7 is a bottom view thereof; and,
FIG. 8 is top, rear, right side perspective view thereof.
The short dash-long dash broken lines illustrate boundaries of the claimed design and form no part of the claimed design. The dash-dash broken lines illustrate portions of the infusion pump cassette that form no part of the claimed design.-
公开(公告)号:US20240350543A1
公开(公告)日:2024-10-24
申请号:US18638229
申请日:2024-04-17
发明人: Katy Rezvani , Rafet Basar , Paul Lin , Michael David Curley , LeeAnn Talarico , Prashanth Vishwanath , James Wilson Meador, III
IPC分类号: A61K35/17 , A61K9/00 , A61K39/00 , A61P35/00 , C07K14/54 , C07K14/705 , C07K14/725 , C07K16/28 , C12N15/85
CPC分类号: A61K35/17 , A61K9/0019 , A61K39/4611 , A61K39/4613 , A61K39/464417 , A61P35/00 , C07K14/5443 , C07K14/7051 , C07K14/70521 , C07K16/2878 , C12N15/85 , A61K2239/13 , A61K2239/21 , A61K2239/22 , C07K2317/53 , C07K2317/565 , C07K2317/622
摘要: The present application provides BCMA targeting chimeric antigen receptor (CAR) comprising a BCMA binding region and an intracellular costimulatory domain derived from DAP10. Further provided are engineered immune effector cells (such as NK cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号:US20240343721A1
公开(公告)日:2024-10-17
申请号:US18635839
申请日:2024-04-15
发明人: Masahiro ITO , Hideyuki SUGIYAMA , Takeshi YAMAMOTO , Keiko KAKEGAWA , Jinxing LI , Junsi WANG , Takahito KASAHARA , Masato YOSHIKAWA
IPC分类号: C07D413/14 , A61P25/28 , C07D413/10
CPC分类号: C07D413/14 , A61P25/28 , C07D413/10
摘要: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号:US20240317733A1
公开(公告)日:2024-09-26
申请号:US18449326
申请日:2023-08-14
发明人: Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号: C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号: C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubral pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.-
公开(公告)号:US20240306632A1
公开(公告)日:2024-09-19
申请号:US18274988
申请日:2022-02-09
发明人: Shuxia ZHOU , Yana WANG , Lan CAO , Dayong GAO , Qiong XUE , Jiusong SUN , Huang ZHU
IPC分类号: A01N1/02
CPC分类号: A01N1/0221 , A01N1/0226
摘要: The present disclosure provides, among other things, a cryopreservation medium comprising a cryoprotectant, an albumin, a disaccharide and a non-pyrogenic and isotonic crystalloid solution. The disclosure also provides, among other things, a cryopreservation medium for cryopreserving immune cells, the medium comprising: human serum albumin (HSA), sodium chloride, sodium gluconate, sodium acetate trihydrate, potassium chloride, magnesium chloride, dimethyl sulfoxide (DMSO), and a trehalose. The present disclosure also provides, a method of cryopreserving immune cells, transporting and subsequently administering such immune cells to a patient in need thereof.
-
公开(公告)号:US20240279737A1
公开(公告)日:2024-08-22
申请号:US18248604
申请日:2021-10-12
发明人: Hiroshi SUGIMOTO , Xiaodong FANG
IPC分类号: C12Q1/6881 , C12Q1/6806 , C12Q1/6851
CPC分类号: C12Q1/6881 , C12Q1/6851 , C12Q1/6806 , C12Q2600/156 , C12Q2600/166
摘要: Provided herein, among other things, is a method of determining a transgene copy number in a biological sample, the method comprising: (a) extracting genomic DNA (gDNA) from the biological sample using an automated process, thus isolating gDNA; (b) performing digital droplet PCR (ddPCR) on the isolated gDNA using one or more primers to amplify a transgene of interest and to amplify a reference gene, thus normalizing gDNA input; and (c) determining transgene copy number in the biological sample.
-
公开(公告)号:USD1039135S1
公开(公告)日:2024-08-13
申请号:US29831177
申请日:2022-03-17
设计人: John Kenneth Hainsworth , Matthew John Garwood , Matthew Ian Murchie , Hong Choo Tang , Fabian Ghoshal
摘要: FIG. 1 is a top, front, left side perspective view of an infusion pump;
FIG. 2 is top, rear, right side perspective view thereof;
FIG. 3 is a front elevation view thereof;
FIG. 4 is a rear elevation view thereof;
FIG. 5 is a left side elevation view thereof;
FIG. 6 is a right side elevation view thereof;
FIG. 7 is a top plan view thereof; and,
FIG. 8 is a bottom view thereof.
The short dash-long dash broken lines illustrate boundaries of the claimed design and form no part of the claimed design. The dash-dash broken lines illustrate portions of the infusion pump that form no part of the claimed design.-
8.
公开(公告)号:US12054474B2
公开(公告)日:2024-08-06
申请号:US17962781
申请日:2022-10-10
发明人: Colm Carroll , Anne Goldby , Martin Teall
IPC分类号: A61K31/454 , A61K31/4545 , A61K45/06 , C07D211/96 , C07D401/12 , C07D401/14
CPC分类号: C07D401/12 , A61K31/454 , A61K31/4545 , A61K45/06 , C07D211/96 , C07D401/14
摘要: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof.
in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.-
9.
公开(公告)号:US20240247067A1
公开(公告)日:2024-07-25
申请号:US18355975
申请日:2023-07-20
发明人: Rachael L. BRAKE , Eric H. WESTIN
CPC分类号: C07K16/2845 , A61P35/00 , A61P37/06 , C07K16/2803 , C07K16/2818 , C07K16/2839 , C07K16/2878 , A61K2039/507 , C07K2317/565 , C07K2317/76
摘要: The invention provides, inter alia, methods of reducing gastrointestinal immune-related adverse events, such as colitis and diarrhea, in subjects undergoing an immune treatment, such as an immune oncology treatment, such as anti-CTLA4 antibody and anti-PD-1 antibody combination treatment for melanoma. In certain aspects, the methods encompass administering a therapeutically effective amount of a polypeptide that inhibits MAdCAM-integrin binding, such as an anti-α4β7 integrin antibody, such vedolizumab or a related antibody.
-
公开(公告)号:US20240228488A1
公开(公告)日:2024-07-11
申请号:US18550306
申请日:2022-03-16
发明人: Nikolaos PAPAIOANNOU , Jeremy Mark TRAVINS , Sarah Jocelyn FINK , John Mark ELLARD , Alastair RAE , Jonathan Andrew SPENCER , Stuart Shane RANKIN , Robert Staurt Laurie CHAPMAN
IPC分类号: C07D471/04 , C07D519/00
CPC分类号: C07D471/04 , C07D519/00
摘要: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
-
-
-
-
-
-
-
-
-